FDA– tag –
-
Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization
PR Newswire (via USA News Group) USA Overview Avaí Bio has achieved a critical manufacturing milestone by completing its GMP-grade Master Cell Bank (MCB) for the alpha-Klotho anti-aging program. This MCB ensures a high-quality, standardi... -
Exosome Therapy Shows Promising Early Clinical Results for Skin Rejuvenation and Hair Loss Treatment, Facing Regulatory Approval Challenges
Skin Therapy Letter USA Overview Exosome therapy, functioning as an intercellular messenger carrying stem cell-derived growth factors and proteins, demonstrates promising early clinical results in both skin rejuvenation and hair loss tre... -
Intellia Therapeutics Bolsters Market Value with Soaring Stock Price and Improved Financials Amid Positive CRISPR Gene Editing Regulatory Progress
Fintel USA Overview Intellia Therapeutics saw its stock price climb to $12.60 per share, marking a 35.12% year-over-year increase by May 2026, boosting its market capitalization to $1.91 billion. The company also improved its net loss in... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
FDA Clears Dexcom Stelo: First Over-the-Counter Continuous Glucose Monitor to Transform Non-Insulin-Dependent Diabetes Management
U.S. Food and Drug Administration (FDA) News Release USA Overview The U.S. FDA has cleared the Dexcom Stelo Glucose Biosensor System, the first over-the-counter (OTC) continuous glucose monitor (CGM) for individuals aged 18 and older not... -
Dexcom G7 15 Day Secures FDA Clearance: Longest-Lasting, Highly Accurate CGM System Redefines Diabetes Management
Dexcom News Release USA Overview Dexcom announced FDA clearance for its G7 15 Day, the longest-lasting (15 days) and most accurate continuous glucose monitoring (CGM) system for people with diabetes aged 18 and older. Boasting an impress... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ... -
iPSC Clinical Trials Deliver Breakthroughs: Parkinson’s, Heart Failure, Cancer Immunotherapies Show Promising Results
Americord Registry USA Overview Induced pluripotent stem cell (iPSC) research is rapidly transforming medicine, with multiple clinical trials reporting significant progress across diverse disease areas. A Kyoto University Hospital trial ... -
Pharmaceutical Membrane Filtration Market: Size, Share, and Growth Forecast to 2034 – A Straits Research Overview
Straits Research Germany Overview This article provides an overview of a market research report published by Straits Research, detailing the pharmaceutical membrane filtration market's current status and projected growth to 2034. The rep... -
Form Bio Launches FormManufacturing: An AI-Driven End-to-End Platform for Genetic Medicine Design and Manufacturing Optimization
Morningstar USA Overview Form Bio has introduced FormManufacturing™, an AI-driven, end-to-end platform for predicting, optimizing, and monitoring manufacturability of genetic medicines, debuting with an AAV-focused offering. Integrating ...
